- Home
- CHWY vs UTHR Comparison
CHWY vs UTHR Comparison
Compare CHWY & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHWY
- UTHR
- Stock Information
- Founded
- CHWY 2010
- UTHR 1996
- Country
- CHWY United States
- UTHR United States
- Employees
- CHWY N/A
- UTHR N/A
- Industry
- CHWY Catalog/Specialty Distribution
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- CHWY Consumer Discretionary
- UTHR Health Care
- Exchange
- CHWY Nasdaq
- UTHR Nasdaq
- Market Cap
- CHWY 16.5B
- UTHR 13.8B
- IPO Year
- CHWY 2019
- UTHR 1999
- Fundamental
- Price
- CHWY $37.53
- UTHR $453.07
- Analyst Decision
- CHWY Strong Buy
- UTHR Buy
- Analyst Count
- CHWY 25
- UTHR 15
- Target Price
- CHWY $45.17
- UTHR $459.60
- AVG Volume (30 Days)
- CHWY 10.1M
- UTHR 874.5K
- Earning Date
- CHWY 09-10-2025
- UTHR 10-29-2025
- Dividend Yield
- CHWY N/A
- UTHR N/A
- EPS Growth
- CHWY N/A
- UTHR 17.94
- EPS
- CHWY 0.35
- UTHR 25.63
- Revenue
- CHWY $12,345,235,000.00
- UTHR $3,077,800,000.00
- Revenue This Year
- CHWY $8.77
- UTHR $13.71
- Revenue Next Year
- CHWY $7.09
- UTHR $5.38
- P/E Ratio
- CHWY $107.45
- UTHR $17.68
- Revenue Growth
- CHWY 9.17
- UTHR 17.62
- 52 Week Low
- CHWY $26.28
- UTHR $266.98
- 52 Week High
- CHWY $48.62
- UTHR $455.12
- Technical
- Relative Strength Index (RSI)
- CHWY 44.81
- UTHR 71.57
- Support Level
- CHWY $36.92
- UTHR $415.00
- Resistance Level
- CHWY $40.55
- UTHR $442.01
- Average True Range (ATR)
- CHWY 1.29
- UTHR 12.96
- MACD
- CHWY 0.06
- UTHR -0.38
- Stochastic Oscillator
- CHWY 16.80
- UTHR 96.49
About CHWY Chewy Inc.
Chewy is the largest e-commerce petcare retailer in the US, generating $11.9 billion in fiscal 2024 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods like crates, leashes, and bowls.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.